Pharmaxis has announced
“significant headline results” for the
first stage of an international Phase
III trial of Bronchitrol (inhaled
mannitol) in patients with cystic
fibrosis.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 17 May 14 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 May 14
AUSTRALIAN Pharmaceutical Industries has refined tactical sales activity and continues to develop exclusive products and range extensions, as part of a strategy to combat weak consumer demand which saw the company report a 24.9% decline in H1 net profit to $24.9 million (PD breaking news).